Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | BCL2L11 | O43521 | 4/20 | 0.35 |
| ▸ | BCL2 | P10415 | 4/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895849 | 0.90 | P2RX7 (0.39) | DPP4DPP7DPP8RIPK1BCL2L11 | |
| SCHEMBL4895858 | 0.90 | P2RX7 (0.39) | DPP4DPP7DPP8RIPK1BCL2L11 | |
| SCHEMBL4895863 | 0.90 | P2RX7 (0.39) | DPP4DPP7DPP8RIPK1BCL2L11 | |
| SCHEMBL4890703 | 0.88 | DPP4 (0.44) | DPP4DPP7DPP8 | |
| SCHEMBL4897042 | 0.88 | DPP4 (0.44) | DPP4DPP7DPP8 | |
| SCHEMBL8272695 | 0.87 | DPP4 (0.47) | DPP4DPP7DPP8P2RX7 | |
| SCHEMBL4916150 | 0.87 | DPP4 (0.47) | DPP4DPP7DPP8P2RX7 | |
| SCHEMBL4891506 | 0.87 | DPP4 (0.47) | DPP4DPP7DPP8P2RX7 | |
| SCHEMBL4890305 | 0.87 | DPP4 (0.47) | DPP4DPP7DPP8P2RX7 | |
| SCHEMBL8273808 | 0.85 | DPP4 (0.47) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | DPP4 1/4885DPP7 4/4885DPP8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.